hVIVO (LSE:HVO) has entered into a clinical trial agreement with Traws Pharma to conduct a Phase 2a human challenge study evaluating tivoxavir marboxil, an oral, single-dose antiviral candidate designed to treat both seasonal and avian influenza.
The randomised, double-blind, placebo-controlled trial will be carried out at hVIVO’s quarantine facilities in Canary Wharf and is expected to enrol around 150 healthy participants through its FluCamp volunteer recruitment platform. The study will also utilise the company’s in-house virology laboratories, with the majority of associated revenue anticipated to be recognised during 2026.
This agreement highlights hVIVO’s strategy of leveraging its refined influenza human challenge model and integrated clinical capabilities to deliver faster and more controlled efficacy data compared with conventional field trials. The approach strengthens its role as a comprehensive clinical development partner. For Traws Pharma, the collaboration is intended to generate high-quality clinical data on the safety and effectiveness of its antiviral candidate, supporting further development in a significant global respiratory disease market.
From an investment perspective, the company’s outlook is supported by solid financial performance and an appealing valuation profile. Strong revenue growth and low leverage provide a favourable foundation within the biotechnology sector. While technical indicators point to positive momentum, the shares remain below key moving averages, which may indicate near-term resistance. A relatively low P/E ratio and a reasonable dividend yield further enhance its appeal to value and income-focused investors.
More about hVIVO plc
hVIVO plc is a specialised, full-service clinical development company and a global leader in human challenge trials. It works with seven of the world’s ten largest biopharmaceutical companies, offering an end-to-end platform that spans preclinical planning through to Phase II studies, alongside advanced laboratory services. The business operates across four core areas: consulting, clinical trials, human challenge studies, and laboratory services, with facilities in the UK and Germany.
Leave a Reply